Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …

This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …

Background: Although rivaroxaban has demonstrated consistent drug levels in normal
weight and obese patients, sufficient confirmation of equal clinical effectiveness and safety is …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …

Anticoagulants are frequently used as thromboprophylaxis and in patients with atrial
fibrillation (AF) or venous thromboembolism (VTE). While obesity rates are reaching …

Purpose To review the literature on treatment of venous thromboembolism (VTE) and
prevention of cardioembolic stroke with direct-acting oral anticoagulants (DOACs) in low …

Aims This study sought to determine the impact of weight and body mass index (BMI) on the
safety and efficacy of direct-acting oral anticoagulants (DOACs) compared with warfarin in …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …